about
Unlocking the secrets to protein-protein interface drug targets using structural mass spectrometry techniquesCore-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkersPCA disjoint models for multiclass cancer analysis using gene expression data.Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.Protein painting reveals solvent-excluded drug targets hidden within native protein-protein interfaces.Synthesis and characterization of hydrogel particles containing Cibacron Blue F3G-AUse of a novel chagas urine nanoparticle test (chunap) for diagnosis of congenital chagas disease.The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics.The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease.Chemokine-Releasing Nanoparticles for Manipulation of Lymph Node MicroenvironmentMultifunctional core-shell nanoparticles: discovery of previously invisible biomarkers.Use of a Chagas Urine Nanoparticle Test (Chunap) to Correlate with Parasitemia Levels in T. cruzi/HIV Co-infected Patients.Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis.Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH.Toward the identification of a tolerogenic signature in IDO-competent dendritic cells.Reactive oxygen species activate NFκB (p65) and p53 and induce apoptosis in RVFV infected liver cells.Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles.Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro.Analysis of urinary human growth hormone (hGH) using hydrogel nanoparticles and isoform differential immunoassays after short recombinant hGH treatment: preliminary results.A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serumApplication of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals.Effects of dexamethazone on LPS-induced activationand migration of mouse dendritic cells revealed by a genome-wide transcriptional analysis.Contact profilometry and correspondence analysis to correlate surface properties and cell adhesion in vitro of uncoated and coated Ti and Ti6Al4V disks.Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity.Hydrogel nanoparticle harvesting of plasma or urine for detecting low abundance proteins.A critical role for lipophosphoglycan in proinflammatory responses of dendritic cells to Leishmania mexicana.Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery.Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemiaNanotechnology in clinical proteomics
P50
Q28087729-7A29F1B7-DF37-4FD3-974C-88AE3AA69145Q28474977-527C6B5E-D59E-4A76-82CB-5A43D6209CAFQ30778992-ABFDB3D3-EE32-4E87-BD79-B315C67EACFFQ33605010-97655F0F-698D-4C13-B0E0-7B2AC7AEE67DQ33942315-2FA050AF-E057-4FCD-8206-9DBF7BDD709EQ34146442-80673AE0-4100-4CD2-95F1-FAE9C7AAC040Q34282008-415C63ED-B1F0-46AD-BC42-3C0917E5DE3FQ34399316-247F5D45-2279-4F56-ADAC-DB91EC795828Q34483187-3FA742FE-DD02-4DD2-8425-F7E65907C01DQ35383102-0751AB96-05C8-4830-B582-91CFEFC168B7Q35571271-BA61050C-9AE6-490F-A40F-9E473587A332Q35937351-EE0CF6F4-5EF3-4871-8B6A-70FFE225D3C7Q36253022-4DDD4439-C4F5-418A-AA7A-3F189EB67D4AQ37142875-0741ED33-8AEC-4B92-9E72-56DA52664D4DQ37721937-39EC7D75-DD6B-42C3-953F-74685903BE4AQ38317862-3FAE9229-5754-44A9-92EF-3661C18D02FBQ40221530-D6289C1A-AB99-46FA-9949-8E9797AA7073Q40497895-1D299278-FA7D-451F-811B-40FCB9C7E839Q41148526-752FACA9-818B-4004-ABF3-AD8E69CAE8D4Q41411720-A5CC7A26-8A37-467A-BA17-2DCBC80854B5Q41812378-A5295261-960D-4180-81EF-B366F653E67CQ42582922-3B630A07-9FFC-4DB4-9E7D-0A9B1BBE3BE0Q42801722-1C878099-466F-434B-9397-D5923F6821AAQ43903768-F3125245-3BEC-4B38-B6AB-17E71544E873Q47296484-C8192C9A-A33F-4FA0-AFEA-7CFE92E9D54FQ49370842-06DEB93B-F387-4E61-AE6A-8280C63B5F9EQ52940660-6C56E8C5-EA34-4301-863C-337F668CE623Q55518386-D876968C-777F-4F97-9CEF-AEDC948A2C8AQ60170385-960C420B-5BBE-4F2B-B740-B875066E8BF1Q60614508-7D7CDFEE-017B-4442-8F8F-75C88AD3AB60
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Alessandra Luchini
@ast
Alessandra Luchini
@en
Alessandra Luchini
@es
type
label
Alessandra Luchini
@ast
Alessandra Luchini
@en
Alessandra Luchini
@es
prefLabel
Alessandra Luchini
@ast
Alessandra Luchini
@en
Alessandra Luchini
@es
P214
P106
P1153
36086501700
P21
P214
P31
P396
IT\ICCU\CFIV\274506
P496
0000-0003-1599-0214
P569
1977-01-01T00:00:00Z
P735
P7859
viaf-307344909